Three Important Trends in China’s Oncology Innovation Research Seen from CSCO

Behind the nine key directions for science and technology governance, what new opportunities are emerging for researchers and innovative pharmaceutical companies?

At the recently concluded 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), experts from the National Health Commission outlined nine key priorities for strengthening science and technology governance, covering clinical research management, technology transfer, innovation ecosystem development, and international academic collaboration.

From MEDSIR’s perspective, this is not only a policy direction, but also a signal that oncology innovation research in China is entering a new stage—one that places greater emphasis on research quality, collaborative efficiency, and international influence.

Based on the messages released at this year’s CSCO, we have observed three important trends worth noting.

Trend 1: High-quality clinical research is becoming an important source of innovation competitiveness.

This year’s CSCO delivered a clear signal: high-quality clinical research is moving from “supporting innovation” to “defining innovation.” As China’s innovative drugs step onto the global stage, simply proving that a drug works is no longer enough. Truly valuable research needs to respond to unmet clinical needs and generate high-quality evidence that can influence treatment decisions.

The quality of research, rather than the number of studies, is becoming a defining line of innovation competitiveness.

Trend 2: Innovation research is moving from single-point breakthroughs toward collaborative innovation.

CSCO’s emphasis on improving diversified investment mechanisms, promoting technology transfer, and optimizing the innovation ecosystem points to the same conclusion: future oncology innovation will depend more heavily on open collaboration. Efficient connections among researchers, hospitals, industry partners, and academic networks will determine whether a good idea can truly cross the “last mile” from concept to clinic and translate into patient benefit, academic impact, and changes in clinical practice.

Innovation is no longer a breakthrough at a single point, but a resonance across a broader network.

Trend 3: China’s innovation is accelerating its integration into the global research network.

The inclusion of international exchange and collaboration among the nine key priorities suggests that China’s innovation is gradually evolving from an important participant in global research into an important contributor to global innovation. More innovative drugs, research topics, and clinical practice insights originating from China are gaining international attention, further supporting the global reach of China’s research capabilities and academic influence.

Behind these three trends, what capabilities do researchers and innovative pharmaceutical companies need?

As high-quality research, collaborative innovation, and global cooperation become key industry themes, researchers and innovative pharmaceutical companies need more than the ability to execute studies. They need the integrated capability to translate innovative ideas into high-quality evidence, academic influence, and clinical value.

For MEDSIR, participating in oncology innovation research is not about simply making projects “more visible,” nor is it about packaging research as communication content. What we hope to do is work together with researchers, hospitals, academic organizations, and innovative pharmaceutical companies to transform questions that genuinely come from clinical practice into rigorous, executable studies capable of generating evidence.

Many valuable research ideas may begin as a question encountered during diagnosis and treatment, a case discussion, or a researcher’s continued observation of patient needs. The real challenge lies in turning these ideas step by step into clear research questions, sound study designs, and credible clinical evidence and ultimately bringing them back into clinical practice, where they may create change for more patients.

This is why we hope to be part of this process.

We hope to help researchers stay focused on the scientific questions themselves, so that truly valuable clinical observations and research ideas can receive more systematic discussion, more rigorous design, and more consistent advancement.

We also hope to work with innovative pharmaceutical companies from the starting point of patient needs and clinical value, considering what questions an innovative asset can answer, what evidence it can help generate, and how it can create more meaningful academic and clinical value through real research collaboration.

In this process, MEDSIR hopes to serve as a connector and a partner:

• Connecting scientific questions with research methodologies

• Connecting local clinical practice with international research networks

• Connecting innovation itself with the people it ultimately hopes to serve patients

Because what truly matters is never only whether a study can be completed or whether a result can be published, but whether it can move medical understanding one step forward and have the opportunity to translate into better treatment options and patient benefit in the future.

To help research ideas truly rooted in clinical needs become innovative studies worthy of global attention.

To help more oncology innovation from China create longer-term value through international exchange and clinical practice.